Degradation of AMPK‐α1 sensitizes BRAF inhibitor‐resistant melanoma cells to arginine deprivation

Melanomas harboring BRAF mutation (V600E) are known to recur frequently following treatment with BRAF inhibitors (BRAFi) despite a high initial response rate. Our previous study has uncovered that BRAFi‐resistant melanoma (BR) cells are vulnerable to arginine deprivation. It has been reported that n...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Ying‐Ying, Wu, Chunjing, Shah, Sumedh S., Chen, Shu‐Mei, Wangpaichitr, Medhi, Kuo, Macus T., Feun, Lynn G., Han, Xiaoqing, Suarez, Miguel, Prince, Jeffrey, Savaraj, Niramol
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5709618/
https://www.ncbi.nlm.nih.gov/pubmed/29094484
http://dx.doi.org/10.1002/1878-0261.12151

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5709618/
https://www.ncbi.nlm.nih.gov/pubmed/29094484
http://dx.doi.org/10.1002/1878-0261.12151

Ejemplares similares